Ann: Positive safety data from 4th Cohort -Phase I Clinical Trial, page-11

I was just going if this. Can’t remember who originally posted it and haven’t been through all the presentations so not sure which one this slide is from.

To be honest the trial being run in total mg and mg/kg made things a little messy for me, until I tried to wrap my head around it.
Be nice if they spelt out the average trial cohort mg/kg dosing at the conclusion of the trial or each cohort stage. Would make it easier for new investors to understand of when we hit the stage of dosing safely through the efficacious zone.